Back to today’s briefing

Story perspectives

Eli Lilly Shares Plunge 14% Despite Revenue Surge

8/8/2025

50 4

Summary

Eli Lilly's Stock Plunge

Eli Lilly's shares took a nosedive, dropping 14% on August 7, 2025, despite a remarkable 38% surge in revenue to $15.56 billion, fueled by robust sales of Zepbound and Mounjaro. The setback stemmed from disappointing Phase 3 trial results for orforglipron, revealing lackluster weight loss outcomes and sparking fears about its competitiveness against rivals like Novo Nordisk.

Summary

Eli Lilly's Weight Loss Breakthrough

Eli Lilly's groundbreaking oral medication, orforglipron, has demonstrated remarkable potential in a Phase 3 trial, enabling participants to shed an average of 12% of their body weight over 72 weeks. With over 3,000 adults involved, Lilly is set to seek regulatory approval by year-end, paving the way for a global launch next year despite mixed market reactions.

1 of 2

Eli Lilly's Stock Plunge

Eli Lilly's shares took a nosedive, dropping 14% on August 7, 2025, despite a remarkable 38% surge in revenue to $15.56 billion, fueled by robust sales of Zepbound and Mounjaro. The setback stemmed from disappointing Phase 3 trial results for orforglipron, revealing lackluster weight loss outcomes and sparking fears about its competitiveness against rivals like Novo Nordisk.

1 / 2